Childhood Neurometabolic Neurodegeneration

Major disease categories and presentations: 1) Lysosomal storage diseases - mucopolysaccharidoses (MPS I/Hurler-Scheie, MPS II/Hunter, MPS III/Sanfilippo, MPS VI/Maroteaux-Lamy) with skeletal, organomegaly, neurodegeneration; sphingolipidoses (Tay-Sachs, Niemann-Pick A/B, Krabbe, metachromatic leukodystrophy, Fabry); 2) Peroxisomal - X-linked adrenoleukodystrophy (cerebral form age 5-12, Addison-only form, AMN), Zellweger syndrome (severe, postnatal failure); 3) Mitochondrial - Leigh syndrome (basal ganglia/brainstem necrosis, lactic acidosis), MELAS (stroke-like episodes, lactic acidosis), MERRF (myoclonic epilepsy, ragged red fibers), Alpers (hepatocerebral, POLG mutation), Pearson syndrome (sideroblastic anemia, pancreas), Kearns-Sayre; 4) Neuronal ceroid lipofuscinoses (NCL/Batten) - 13 known genes (CLN1-CLN13), infantile, late-infantile, juvenile, adult forms; characterized by progressive blindness, seizures, dementia, motor decline; 5) Aminoacidopathies - PKU (treatable with diet), maple syrup urine disease (MSUD - branched chain), homocystinuria, tyrosinemia; treatable with diet/enzyme; 6) Organic acidemias - methylmalonic, propionic, isovaleric acidemia; episodic crises with metabolic acidosis, hyperammonemia, neurologic deterioration; 7) Urea cycle disorders - OTC deficiency, citrullinemia, ASA; severe hyperammonemia; 8) Energy metabolism - GLUT1 deficiency (early-onset epilepsy, ataxia, paroxysmal exertional dyskinesia, treatable with ketogenic diet); 9) Sphingolipid - Niemann-Pick C (vertical gaze palsy, ataxia, splenomegaly, dementia), GM1/2 gangliosidoses (cherry-red spot, neurodegeneration); 10) Common features - regression after normal development period (varies by disorder), seizures, ataxia, dystonia, spasticity, vision/hearing loss, dementia, organomegaly, dysmorphology, organ-specific findings.

Diagnostic approach: 1) Clinical clues - regression after normal interval (most important sign), neurologic decline pattern (cortical, subcortical, basal ganglia, cerebellar, peripheral), associated systemic findings (cardiomyopathy, hepatomegaly, splenomegaly, renal, dysmorphology, skin), family history (consanguinity, prior affected siblings, X-linked); 2) Initial laboratory - CBC, basic metabolic, liver, lactate, ammonia, blood pH, urinalysis, urine organic acids, urine amino acids, plasma amino acids, plasma carnitine, acylcarnitines, blood gas; 3) Specialized testing - leukocyte enzymes (lysosomal), urine glycosaminoglycans (MPS), VLCFA (peroxisomal), pipecolic acid, copper studies, ceruloplasmin, mitochondrial markers (lactate-pyruvate ratio, lactic acid CSF, mitochondrial DNA, muscle biopsy with histochemistry and respiratory chain enzymes), CSF lactate/pyruvate, CSF amino acids; 4) Imaging - MRI brain (specific patterns: leukodystrophy distinguishing white matter primary vs secondary, basal ganglia involvement, atrophy patterns, MR spectroscopy for lactate, NAA, choline), MRI spine if appropriate; 5) Genetic testing - rapid whole-exome sequencing or trio analysis (yield 30-40% in undiagnosed neurodegeneration); targeted gene panels (neurometabolic, mitochondrial, leukodystrophy panels); chromosomal microarray; expanded newborn screening retrospective review; 6) Tissue biopsy - rarely needed with current diagnostic capabilities; muscle biopsy still useful in mitochondrial; skin fibroblast culture for enzyme studies; 7) Newborn screening - tandem mass spectrometry detects 40+ inborn errors of metabolism; expanding to lysosomal disorders (Pompe, Krabbe, MPS I) in some regions; presymptomatic detection enables early intervention.

Treatment, family counseling, and outcomes: 1) Disease-specific treatments - enzyme replacement therapy (Pompe, Hunter, Hurler-MPS I, Fabry, Gaucher, Niemann-Pick B); intrathecal enzyme replacement for some MPS (CNS access challenge); substrate reduction therapy (Niemann-Pick C - miglustat); gene therapy (cerebral ALD with autologous lentiviral CD34+ cells - elivaldogene; gene therapies for SMA, MPS, ALD in development/approval); hematopoietic stem cell transplantation (Hurler/MPS I, MPS VII, ALD presymptomatic, MLD before significant neurodegeneration, Krabbe presymptomatic); 2) Dietary management - PKU (low-phenylalanine), MSUD (low branched chain), GA-1 (lysine restriction), tyrosinemia I (NTBC + low protein), galactosemia (lactose elimination); strict lifelong; 3) Cofactor therapy - biotin (multiple carboxylase deficiency), pyridoxine (B6-responsive seizures), folinic acid, BH4 (sapropterin in some PKU), thiamine (MSUD subset, mitochondrial); 4) Symptomatic management - antiepileptics, motor disorder management (botulinum, intrathecal baclofen, deep brain stimulation), dystonia management, behavioral medications, palliative care; 5) Family support - genetic counseling, prenatal/preimplantation diagnosis, carrier screening, family screening, psychosocial support, social services for caregiving; 6) Outcomes - varies dramatically by disease; treatable disorders with early intervention have favorable outcomes; many remain progressive with limited disease-modifying therapy; supportive care extends life and quality; 7) Ethical considerations - newborn screening implications, presymptomatic intervention, end-of-life care, research participation; 8) Multidisciplinary care - metabolic specialist, neurologist, geneticist, dietitian, social worker, palliative care, school liaison, family support; 9) Modern advances - newborn screening expansion, rapid genomic diagnosis (24-72 hours possible), gene therapy approval, targeted small molecule therapies, expanded compassionate use; 10) Future - mRNA therapy, base editing, prime editing, antisense oligonucleotides, more gene therapies, improved screening, prenatal therapy potential.